Orgenesis Inc. · OTC:ORGS
Orgenesis — Corporate Update (May 2020)
9 slides from Orgenesis's corporate update, May 6, 2020
Slide 1: Technology overview: Fighting COVID-19
@rgenesis” | Technology overview ; Fighting COVID-19 May 2020 Proprietary and Confidential information
Slide 2: Forward Looking Statements
@rgenesis Forward Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking sta
Slide 3: Fighting COVID-19
@rgenesis FIGHTING COVID-19 1. BioShield program 2. Ranpirnase, a potent anti-viral candidate 3. Whole cell vaccination program
Slide 4: BioShield COVID19: First Line Antibody Development
@rgenesis” BIOSHIELD COVID19 FIRST LINE ANTIBODY DEVELOPMENT
Slide 5: Advantages and Mechanism of Rapid Discovery/Generation of Novel Neutralizing Antibodies
Advantages and Mechanism of Rapid Discovery/Generation of Novel Neutralizing Antibodies =, we -Y h EPIDEMIC: |EMOGE! | & Optimal resources allocation (need only 1# unit) Inexpensive development Fast - No need to know a protein or a toxin from a pathogen that must be targeted to provide adequate prot
Slide 6: Ranpirnase COVID19: Antiviral Activity
rgenesis” RANPIRNASE COVID19 ANTIVIRAL ACTIVITY
Slide 7: Ranpirnase - a broad spectrum anti-viral
Ranpirnase - a broad spectrum anti Elimination of infected cells Viral eradication + Preferential penetration into infected cells + Degrades viral RNA genome + Degrades miRNA and activates ATF3 ‘+ Blocks translation of viral proteins (tRNA, dsRNA degradation) ‘+ Degrades specific viral miRNAs - dest
Slide 8: Whole Cell Vaccination for Rapid Vaccine Development
Whole Cell Vaccination for Rapid Vaccine Development Permissive Cell Line Unique activating Infected Cells Orgenesis Cells Irradiation Antibodies generation X-Ray Antibody Response and Virus Neutralization Intra-dermal Injection ‘Non-proliferating Cells, ————————— with high virus titer
Slide 9: Rapid Response to pandemics through Orgenesis point-of-care global network
Rapid Response to pandemics through Orgenesis point-of-care global network eee USP covers : 1. Survivors Detection Worldwide 2. Breakthrough ApbHC for cloning pathogen-neutralizing antibodies 3. Quality Control 4. Antibodies closed-system manufacturing in Wallonia